Achieving clinically meaningful quality of life benefits in nocturia takes time: Results from a long-term, multicenter phase 3 study of desmopressin in Japanese patients

What Was Tested

Researchers studied Vasopressin and Desmopressin in this clinical trial, phase iii publication.

Who Took Part

PubMed indexes the participants as middle-aged adults, both men and women.

A long-term, multicenter phase 3 study was conducted that enrolled Japanese male and female patients with nocturia (NCT03051009).

Male patients received desmopressin 25- or 50-μg ODTs, and female patients received desmopressin 25-μg ODTs for up to 1 year.

How the Study Was Run

In design terms this was a multicenter study.

More than one site took part, so the participants came from several places.

The methods mention a period of 1 year.

The primary endpoint was safety.

Secondary endpoints included change from baseline in number of nocturnal voids, time to first awakening to void, and QoL assessments (nocturia-specific zQoL [N-QoL], Insomnia Severity Index [ISI], and Hsu bother score).

What Was Measured

The subject headings attached to it are Deamino Arginine Vasopressin, Japan, Nocturia, Quality of Life, Surveys and Questionnaires and Urological Agents.

The authors tagged it with the keywords desmopressin, nocturnal polyuria and response shift.

What This Means in Plain Language

The paper is a multicenter study of Vasopressin and Desmopressin over 1 year.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2021 (Lower urinary tract symptoms), a journal based in Australia.

More context: the Vasopressin compound page and the Desmopressin compound page, all human trials.